This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc., a leading innovator in the medical device industry, is headquartered in the United States. Founded in 2006, the company has established itself as a pioneer in minimally invasive surgical solutions, particularly in the fields of bariatric and gastrointestinal procedures. With a focus on advanced endoscopic technologies, Apollo Endosurgery offers unique products such as the OverStitch™ Endoscopic Suturing System and the ORBERA® Managed Weight Loss System. These solutions are designed to enhance patient outcomes while minimising recovery times. Recognised for its commitment to innovation, Apollo Endosurgery has achieved significant milestones, positioning itself as a trusted partner in the healthcare community. The company continues to expand its operational reach, serving major markets across North America and beyond, while striving to improve the quality of care for patients worldwide.
DitchCarbon Score
How does Apollo Endosurgery, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apollo Endosurgery, Inc.'s score of 97 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Apollo Endosurgery, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Boston Scientific Corporation, which may influence its climate commitments and emissions reporting. As part of its corporate family relationship, Apollo Endosurgery inherits climate initiatives and targets from Boston Scientific Corporation. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the level of Boston Scientific. However, specific reduction targets or achievements for Apollo Endosurgery have not been disclosed. While no direct emissions data or reduction targets are available for Apollo Endosurgery, the company's alignment with Boston Scientific's sustainability efforts suggests a commitment to addressing climate change and reducing carbon footprints in line with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Apollo Endosurgery, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
